322 related articles for article (PubMed ID: 16059630)
1. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
Niikura K; Takeshita N; Takano M
J Bone Miner Res; 2005 Sep; 20(9):1579-88. PubMed ID: 16059630
[TBL] [Abstract][Full Text] [Related]
2. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
Niikura K; Takano M; Sawada M
Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
[TBL] [Abstract][Full Text] [Related]
3. FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats.
Niikura K; Nakajima S; Takano M; Yamazaki H
Bone; 2007 Apr; 40(4):888-94. PubMed ID: 17157574
[TBL] [Abstract][Full Text] [Related]
4. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
Nyman JK; Väänänen HK
Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
[TBL] [Abstract][Full Text] [Related]
5. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
David P; Nguyen H; Barbier A; Baron R
J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
[TBL] [Abstract][Full Text] [Related]
6. Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice.
Nijenhuis T; van der Eerden BC; Hoenderop JG; Weinans H; van Leeuwen JP; Bindels RJ
J Bone Miner Res; 2008 Nov; 23(11):1815-24. PubMed ID: 18597625
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase.
Laitala T; Väänänen HK
J Clin Invest; 1994 Jun; 93(6):2311-8. PubMed ID: 8200964
[TBL] [Abstract][Full Text] [Related]
8. Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis.
Niikura K
Cancer Chemother Pharmacol; 2007 Sep; 60(4):555-62. PubMed ID: 17187252
[TBL] [Abstract][Full Text] [Related]
9. Vacuolar ATPase as a drug discovery target.
Niikura K
Drug News Perspect; 2006 Apr; 19(3):139-44. PubMed ID: 16804565
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of the effects of a novel vacuolar adenosine 5'-triphosphatase inhibitor, FR202126, and doxycycline on bone loss caused by experimental periodontitis in rats.
Niikura K
J Periodontol; 2006 Jul; 77(7):1211-6. PubMed ID: 16805684
[TBL] [Abstract][Full Text] [Related]
11. A novel synthetic triazolotriazepine derivative JTT-606 inhibits bone resorption by down-regulation of action and production of bone resorptive factors.
Chikazu D; Shindo M; Iwasaka T; Katagiri M; Manabe N; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2000 Apr; 15(4):674-82. PubMed ID: 10780859
[TBL] [Abstract][Full Text] [Related]
12. The a3 isoform vacuolar type H⁺-ATPase promotes distant metastasis in the mouse B16 melanoma cells.
Nishisho T; Hata K; Nakanishi M; Morita Y; Sun-Wada GH; Wada Y; Yasui N; Yoneda T
Mol Cancer Res; 2011 Jul; 9(7):845-55. PubMed ID: 21669964
[TBL] [Abstract][Full Text] [Related]
13. Effects of wortmannin analogs on bone in vitro and in vivo.
Sato M; Bryant HU; Dodge JA; Davis H; Matter WF; Vlahos CJ
J Pharmacol Exp Ther; 1996 Apr; 277(1):543-50. PubMed ID: 8613966
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiological characterization of ATPases in native synaptic vesicles and synaptic plasma membranes.
Obrdlik P; Diekert K; Watzke N; Keipert C; Pehl U; Brosch C; Boehm N; Bick I; Ruitenberg M; Volknandt W; Kelety B
Biochem J; 2010 Mar; 427(1):151-9. PubMed ID: 20100168
[TBL] [Abstract][Full Text] [Related]
15. Ion transporters involved in acidification of the resorption lacuna in osteoclasts.
Henriksen K; Sørensen MG; Jensen VK; Dziegiel MH; Nosjean O; Karsdal MA
Calcif Tissue Int; 2008 Sep; 83(3):230-42. PubMed ID: 18787885
[TBL] [Abstract][Full Text] [Related]
16. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
[TBL] [Abstract][Full Text] [Related]
17. Characterization and cellular distribution of the osteoclast ruffled membrane vacuolar H+-ATPase B-subunit using isoform-specific antibodies.
Mattsson JP; Skyman C; Palokangas H; Väänänen KH; Keeling DJ
J Bone Miner Res; 1997 May; 12(5):753-60. PubMed ID: 9144341
[TBL] [Abstract][Full Text] [Related]
18. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
19. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
Sørensen MG; Henriksen K; Neutzsky-Wulff AV; Dziegiel MH; Karsdal MA
J Bone Miner Res; 2007 Oct; 22(10):1640-8. PubMed ID: 17576165
[TBL] [Abstract][Full Text] [Related]
20. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
